Psychiatryai.com: Real-Time AI Scoping Review (RAISR4D) in Psychiatry and Mental Health with Live Real-World Evidence and CPD/CME for Psychiatrists
Psychiatryai.com was launched in 2021, and its initial research findings were presented at EPA 2023. The platform utilises Artificial Intelligence (AI) and Data Science (DS) to analyse Real-World Evidence (RWE) in psychiatry and mental health from PubMed publications over the past year, providing psychiatrists and healthcare professionals with up-to-date CPD/CME. A review of the site was presented to EPA 2024.
The platform also aims to raise awareness about “Aiatrogenesis.” To address this problem, the site utilises AI and DS technology for the categorisation, meta-analysis, and summarisation of RWE, rather than the production of possibly misleading or false Generative AI evidence (Monteith et al. BJP 2023; 1-3).
Overall, PsychiatryAI.com has successfully developed a novel AI and DS platform that transforms the latest psychiatry and mental health research from PubMed into clinically relevant Real-World CME/CPD modules through advanced Real-Time AI Scoping Review semantic technology. By continuously synthesising emerging scientific knowledge, the platform empowers psychiatrists and healthcare professionals worldwide with AI and data-driven insights while delivering a next-generation CPD/CME ecosystem comprising more than 23,000 open-access learning modules. This enhances hypothesis testing in mental health and psychiatric research with AI (RAISR4D).
The site is VR-ready and has a special focus on AI and Psychiatry, Disaster and Traumatology Sciences, and Youth Mental Health.
Dr Paras Naik, Specialty Doctor in Psychiatry, Berkshire Healthcare NHS Foundation Trust
Developer and Founder – Psychiatryai.com
Psychiatryai.com AI Semantic Algorithm
